GRAIL Inc. (GRAL) vs Ligand Pharmaceuticals Incorporated (LGND)
A side-by-side comparison of GRAIL Inc. and Ligand Pharmaceuticals Incorporated across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GRAL
GRAIL Inc.
$138.89HealthcareDelayed quote: Oct 6, 2026, 12:10 PM EDT
LGND
Ligand Pharmaceuticals Incorporated
$297.70HealthcareDelayed quote: Oct 6, 2026, 12:10 PM EDT
Total return — GRAL vs LGND
growth of $100 · dividends reinvested · last 2yGRAL +1028.0% (+235.9%/yr)LGND +279.5% (+94.8%/yr)GRAL compounded faster over this window
GRAL LGND
GRAL vs LGND: by the numbers
- •LGND is the larger company ($5.97B vs $5.96B market cap).
- •LGND is profitable (67.88% net margin) while GRAL runs a net loss (-236.95%).
Metrics side by side
Valuation
| Metric | GRAL | LGND |
|---|---|---|
| P/E ratio | N/A | 31.84 |
| Forward P/E | N/A | 31.99 |
| P/S ratio | 36.07 | 20.53 |
| P/B ratio | 2.34 | 6.17 |
| EV / EBITDA | N/A | 45.13 |
| FCF yield | N/A | 2.20% |
Profitability
| Metric | GRAL | LGND |
|---|---|---|
| Gross margin | -42.52% | 98.58% |
| Operating margin | -362.95% | 17.61% |
| Net margin | -236.95% | 67.88% |
| ROE | -15.40% | 20.38% |
| ROIC | -20.26% | 3.91% |
Growth (annualized)
| Metric | GRAL | LGND |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 2.92% |
| FCF CAGR (5Y) | N/A | -0.49% |
| Total return CAGR (5Y) | N/A | 30.72% |
Frequently asked
- Is GRAL or LGND more profitable?
- LGND runs the higher net margin — GRAL at -236.95% versus LGND at 67.88%.
Go deeper
Dig into the metrics
Ligand Pharmaceuticals P/E ratioGRAIL ROELigand Pharmaceuticals ROEGRAIL operating marginLigand Pharmaceuticals operating marginGRAIL revenue growthLigand Pharmaceuticals revenue growthGRAIL free cash flowLigand Pharmaceuticals free cash flow
GRAIL & Ligand Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.